Skip to content

Clinical trials

Phase 1 Movement Disorders trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Movement Disorders Phase: Phase 1 Clear all

22 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20011
20051
20071
20081
20091
20113
20121
20131
20151
20161
20171
20181
20191
20221
20241
20252
20262

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed14
Recruiting3
Not yet recruiting2
Terminated2
Unknown status1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Institute of Neurological Disorders and Stroke (NINDS)3
University Children's Hospital, Zurich3
Siena Biotech S.p.A.2
Biogen1
Cerevel Therapeutics, LLC1
Denali Therapeutics Inc.1
Heinrich-Heine University, Duesseldorf1
Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd.1
Michael J. Fox Foundation for Parkinson's Research1
Neurocrine Biosciences1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Movement Disorders22
Parkinson Disease12
Neurodegenerative Diseases7
Central Nervous System Diseases6
Nervous System Diseases6
Brain Diseases5
Dyskinesias4
Basal Ganglia Diseases3
Essential Tremor3
Huntington Disease3

Trials

Showing 76 to 22 of 22. Each trial links to its page on Pharma Observatory.

No trials match these filters.

Try a different keyword, or clear a filter.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.